AR076153A1 - Forma de dosificacion intra-oral de multiples porciones con propiedades organolepticas. formulaciones - Google Patents
Forma de dosificacion intra-oral de multiples porciones con propiedades organolepticas. formulacionesInfo
- Publication number
- AR076153A1 AR076153A1 ARP100100980A ARP100100980A AR076153A1 AR 076153 A1 AR076153 A1 AR 076153A1 AR P100100980 A ARP100100980 A AR P100100980A AR P100100980 A ARP100100980 A AR P100100980A AR 076153 A1 AR076153 A1 AR 076153A1
- Authority
- AR
- Argentina
- Prior art keywords
- nicotine
- dosage form
- component
- intra
- oral dosage
- Prior art date
Links
- 239000006186 oral dosage form Substances 0.000 title abstract 8
- 239000000203 mixture Substances 0.000 title abstract 4
- 229920000858 Cyclodextrin Polymers 0.000 abstract 8
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 7
- 229960002715 nicotine Drugs 0.000 abstract 7
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 7
- 229940097362 cyclodextrins Drugs 0.000 abstract 5
- -1 hydroxypropyl Chemical class 0.000 abstract 5
- 208000025569 Tobacco Use disease Diseases 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 238000004090 dissolution Methods 0.000 abstract 4
- 239000013543 active substance Substances 0.000 abstract 3
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 abstract 2
- MYKUKUCHPMASKF-VIFPVBQESA-N (S)-nornicotine Chemical compound C1CCN[C@@H]1C1=CC=CN=C1 MYKUKUCHPMASKF-VIFPVBQESA-N 0.000 abstract 2
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 abstract 2
- MYKUKUCHPMASKF-UHFFFAOYSA-N Nornicotine Natural products C1CCNC1C1=CC=CN=C1 MYKUKUCHPMASKF-UHFFFAOYSA-N 0.000 abstract 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 abstract 2
- 229950006073 cotinine Drugs 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 abstract 2
- 230000001737 promoting effect Effects 0.000 abstract 2
- JUOSGGQXEBBCJB-GORDUTHDSA-N rivanicline Chemical compound CNCC\C=C\C1=CC=CN=C1 JUOSGGQXEBBCJB-GORDUTHDSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 2
- 230000035807 sensation Effects 0.000 abstract 2
- 235000019615 sensations Nutrition 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 abstract 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 abstract 1
- MXYUKLILVYORSK-UHFFFAOYSA-N (+/-)-allo-lobeline Natural products C1CCC(CC(=O)C=2C=CC=CC=2)N(C)C1CC(O)C1=CC=CC=C1 MXYUKLILVYORSK-UHFFFAOYSA-N 0.000 abstract 1
- MXYUKLILVYORSK-HBMCJLEFSA-N (-)-lobeline Chemical compound C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1 MXYUKLILVYORSK-HBMCJLEFSA-N 0.000 abstract 1
- PVPBHKCSQBLDEW-ZQOBQRRWSA-N (1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol 4-hydroxybutane-1-sulfonic acid Chemical compound OCCCCS(O)(=O)=O.OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O PVPBHKCSQBLDEW-ZQOBQRRWSA-N 0.000 abstract 1
- MBQYQLWSBRANKQ-IMTBSYHQSA-N (1s,5s)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane Chemical compound N1=C(Cl)C(Cl)=CC(N2C[C@H]3NC[C@H]3C2)=C1 MBQYQLWSBRANKQ-IMTBSYHQSA-N 0.000 abstract 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 abstract 1
- MTXSIJUGVMTTMU-JTQLQIEISA-N (S)-anabasine Chemical compound N1CCCC[C@H]1C1=CC=CN=C1 MTXSIJUGVMTTMU-JTQLQIEISA-N 0.000 abstract 1
- HFZDMKMXPGRKCK-GQCTYLIASA-N (e)-4-(5-ethoxypyridin-3-yl)-n-methylbut-3-en-1-amine Chemical compound CCOC1=CN=CC(\C=C\CCNC)=C1 HFZDMKMXPGRKCK-GQCTYLIASA-N 0.000 abstract 1
- BCPPKHPWLRPWBJ-GYDOPSIJSA-N (e)-but-2-enedioic acid;3-ethynyl-5-[(2s)-1-methylpyrrolidin-2-yl]pyridine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@H]1C1=CN=CC(C#C)=C1 BCPPKHPWLRPWBJ-GYDOPSIJSA-N 0.000 abstract 1
- XKFMBGWHHBCWCD-QMMMGPOBSA-N 3-[[(2s)-azetidin-2-yl]methoxy]pyridine Chemical compound C([C@H]1NCC1)OC1=CC=CN=C1 XKFMBGWHHBCWCD-QMMMGPOBSA-N 0.000 abstract 1
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 abstract 1
- NVZGJSVPOOILDI-UHFFFAOYSA-N 4-[2-(1-methyl-2-pyrrolidinyl)ethylthio]phenol Chemical compound CN1CCCC1CCSC1=CC=C(O)C=C1 NVZGJSVPOOILDI-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 abstract 1
- RPYWXZCFYPVCNQ-RVDMUPIBSA-N DMXB-A Chemical compound COC1=CC(OC)=CC=C1\C=C/1C(C=2C=NC=CC=2)=NCCC\1 RPYWXZCFYPVCNQ-RVDMUPIBSA-N 0.000 abstract 1
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 abstract 1
- NLPRAJRHRHZCQQ-UHFFFAOYSA-N Epibatidine Natural products C1=NC(Cl)=CC=C1C1C(N2)CCC2C1 NLPRAJRHRHZCQQ-UHFFFAOYSA-N 0.000 abstract 1
- 244000166124 Eucalyptus globulus Species 0.000 abstract 1
- 239000001116 FEMA 4028 Substances 0.000 abstract 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 abstract 1
- JUOSGGQXEBBCJB-UHFFFAOYSA-N Metanicotine Natural products CNCCC=CC1=CC=CN=C1 JUOSGGQXEBBCJB-UHFFFAOYSA-N 0.000 abstract 1
- 241000208125 Nicotiana Species 0.000 abstract 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 abstract 1
- 206010057852 Nicotine dependence Diseases 0.000 abstract 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 abstract 1
- 239000005844 Thymol Substances 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- ILLGYRJAYAAAEW-QMMMGPOBSA-N abt-418 Chemical compound CN1CCC[C@H]1C1=CC(C)=NO1 ILLGYRJAYAAAEW-QMMMGPOBSA-N 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 abstract 1
- 229960005174 ambroxol Drugs 0.000 abstract 1
- 230000004888 barrier function Effects 0.000 abstract 1
- 229960005274 benzocaine Drugs 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 229960004853 betadex Drugs 0.000 abstract 1
- 239000008376 breath freshener Substances 0.000 abstract 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 abstract 1
- 229960001058 bupropion Drugs 0.000 abstract 1
- 239000004075 cariostatic agent Substances 0.000 abstract 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 abstract 1
- 229960003291 chlorphenamine Drugs 0.000 abstract 1
- ODQWQRRAPPTVAG-BOPFTXTBSA-N cis-doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)\C2=CC=CC=C21 ODQWQRRAPPTVAG-BOPFTXTBSA-N 0.000 abstract 1
- 235000009508 confectionery Nutrition 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 abstract 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract 1
- 229960001985 dextromethorphan Drugs 0.000 abstract 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 abstract 1
- 229960000520 diphenhydramine Drugs 0.000 abstract 1
- 229960005426 doxepin Drugs 0.000 abstract 1
- NLPRAJRHRHZCQQ-IVZWLZJFSA-N epibatidine Chemical compound C1=NC(Cl)=CC=C1[C@@H]1[C@H](N2)CC[C@H]2C1 NLPRAJRHRHZCQQ-IVZWLZJFSA-N 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000019634 flavors Nutrition 0.000 abstract 1
- 229960002464 fluoxetine Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000873 masking effect Effects 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 229940041616 menthol Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960001047 methyl salicylate Drugs 0.000 abstract 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 abstract 1
- 229960004644 moclobemide Drugs 0.000 abstract 1
- 229960001158 nortriptyline Drugs 0.000 abstract 1
- 239000006174 pH buffer Substances 0.000 abstract 1
- 229960001802 phenylephrine Drugs 0.000 abstract 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 abstract 1
- 229960003908 pseudoephedrine Drugs 0.000 abstract 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000001953 sensory effect Effects 0.000 abstract 1
- 230000005586 smoking cessation Effects 0.000 abstract 1
- RXLOZRCLQMJJLC-UHFFFAOYSA-N ssr-180,711 Chemical compound C1=CC(Br)=CC=C1OC(=O)N1C(CC2)CCN2CC1 RXLOZRCLQMJJLC-UHFFFAOYSA-N 0.000 abstract 1
- MKTAGSRKQIGEBH-SSDOTTSWSA-N tebanicline Chemical compound C1=NC(Cl)=CC=C1OC[C@@H]1NCC1 MKTAGSRKQIGEBH-SSDOTTSWSA-N 0.000 abstract 1
- 229960000790 thymol Drugs 0.000 abstract 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 abstract 1
- 229960004751 varenicline Drugs 0.000 abstract 1
- 238000004260 weight control Methods 0.000 abstract 1
- 230000002087 whitening effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/32—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Birds (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Forma de dosificacion intra oral de porciones multiples que comprende al menos un agente farmacéuticamente activo o que promueve la salud, en donde al menos una porcion comprende un componente para la creacion de una sensacion organoléptica evidente. Uso de marcadores o senales sensoriales como ayuda conceptual para el sujeto que utilice la forma de dosificacion, por medio del cual la(s) sensacion(es) organolépticas es (son) tales que facilita(n) identificar al sujeto las diferentes porciones y diferenciarlas. Método y un sistema para administrar agentes activos, como nicotina y/o sus metabolitos, tales como por ejemplo cotinina, N' oxido de nicotina, nornicotina, (S) -nicotina-N-Beta-glucuronido y sus mezclas, isomeros, sales y complejos de inclusion, así como también el uso y la produccion de dichas formas de dosificacion. Reivindicacion 9: Una forma de dosificacion intra oral de multiples porciones de acuerdo con cualquiera de las reivindicaciones precedentes, donde las porciones además tienen diferente disolucion y diferentes tiempos de disolucion. Reivindicacion 10: Una forma de dosificacion intra oral de multiples porciones de acuerdo con la reivindicacion 9, donde al menos una porcion se desintegra más rápidamente que al menos otra, y donde cada porcion comprende por lo menos un ítem seleccionado de entre un componente para tratar la dependencia del tabaco, un componente farmacéuticamente activo, un componente que simula a la nicotina, un componente amortiguador de pH, un componente regulador de pH, un sabor, un componente barrera, un componente color, un componente adhesivo, un agente enmascarador de sabor, un agente blanqueador de dientes, un agente para refrescar el aliento, un agente para promover la salud oral, y un agente anticaries. Reivindicacion 23: Una forma de dosificacion intra oral de multiples porciones de acuerdo con la reivindicacion 21, donde el complejo de inclusion de nicotina es un complejo de ciclodextrina, donde la ciclodextrina usada se elige de entre las ciclodextrinas alpha-, beta e y-, derivados hidroxipropilo de ciclodextrinas alpha-, beta- e y-, ciclodextrinas sulfobutiléter, tales como por ejemplo beta-ciclodextrina sulfobutiléter, ciclodextrinas alquilatadas, tales como beta-ciclodextrina metilatada al azar, y ciclodextrinas ramificadas, tales como glucosil- y maltosil-beta-ciclodextrina. Reivindicacion 27: Una forma de dosificacion intra oral de multiples porciones de acuerdo con cualquiera de las reivindicaciones precedentes, que comprende un componente para tratar la dependencia del tabaco seleccionado de entre uno o más de vareniclina, bupropion, nortriptilina, doxepina, fluoxetina, imipramin, moclobemida, conotoxinMll, epibatidina, A-85380, lobelina, anabasina, SIB-1508Y, SIB-1553A, ABT-418, ABT-594, ABT-894, TC-2403, TC-2559, RJR-2403, SSR180711, GTS-21, y/o citisina. Reivindicacion 49: Una forma de dosificacion intra oral de multiples porciones de acuerdo con cualquiera de las reivindicaciones 9 - 27 y 32 - 47, en donde al menos una porcion de rápida disolucion comprende al menos un agente farmacéuticamente activo seleccionado de entre el grupo que consiste en fenilefrina, dextrometorfan, difenhidramina, ambroxol, clorfeniramina, canabidiol, delta-9-tetrahidrocanabinol, clofedianol, y pseudoefedrina, y donde al menos una porcion de disolucion lenta comprende al menos un agente farmacéuticamente activo seleccionado de entre el grupo que consiste en mentol, nicotina, diclonina, benzocaína, timol, salicilato de metilo y eucalipto. Reivindicacion 51: Una forma de dosificacion intra oral de multiples porciones de acuerdo con cualquiera de las reivindicaciones 9 - 27 y 32 - 50 donde al menos una porcion de disolucion rápida es una porcion comprimida y donde al menos una porcion de disolucion lenta tiene una matriz que es un cristal de caramelo duro. Reivindicacion 55: Una formulacion de acuerdo con cualquiera de las reivindicaciones 1 - 27 y 32 - 51 que comprende nicotina y/o sus metabolitos, tales como por ejemplo cotinina, N' oxido de nicotina, nornicotina, (S) -nicotina-N-beta-glucuronido y sus mezclas, isomeros, sales y complejos, en cualquier forma, para ser empleados en terapia, en donde la terapia es el tratamiento de una enfermedad seleccionada de entre el grupo que consiste en dependencia del tabaco o de la nicotina, enfermedad de Alzheimer, mal de Crohn, enfermedad de Parkinson, síndrome de Tourette, colitis ulcerosa y control de peso posterior a haber dejado de fumar.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0900397 | 2009-03-27 | ||
US12/430,238 US20100247586A1 (en) | 2009-03-27 | 2009-04-27 | Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties |
Publications (1)
Publication Number | Publication Date |
---|---|
AR076153A1 true AR076153A1 (es) | 2011-05-18 |
Family
ID=42791088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100100980A AR076153A1 (es) | 2009-03-27 | 2010-03-26 | Forma de dosificacion intra-oral de multiples porciones con propiedades organolepticas. formulaciones |
Country Status (11)
Country | Link |
---|---|
US (1) | US20100247586A1 (es) |
JP (1) | JP2010229131A (es) |
KR (1) | KR20100108307A (es) |
AR (1) | AR076153A1 (es) |
AU (1) | AU2010201229A1 (es) |
BR (1) | BRPI1001980A2 (es) |
CA (1) | CA2697867A1 (es) |
MX (1) | MX2010003550A (es) |
NZ (2) | NZ584267A (es) |
RU (1) | RU2490010C2 (es) |
ZA (1) | ZA201002188B (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004259006B2 (en) * | 2003-07-24 | 2010-10-07 | Glaxosmithkline Llc | Orally dissolving films |
US20100124560A1 (en) * | 2008-11-14 | 2010-05-20 | Mcneil Ab | Multi portion intra-oral dosage form and use thereof |
LT2501234T (lt) | 2009-11-20 | 2017-12-11 | Tonix Pharma Holdings Limited | Būdai ir kompozicijos, skirti simptomų, susijusių su potrauminiu streso sutrikimu, gydymui naudojant ciklobenzapriną |
US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
US11116237B2 (en) | 2010-08-11 | 2021-09-14 | R.J. Reynolds Tobacco Company | Meltable smokeless tobacco composition |
US9155321B2 (en) | 2010-08-11 | 2015-10-13 | R.J. Reynolds Tobacco Company | Meltable smokeless tobacco composition |
US9277976B2 (en) | 2011-01-24 | 2016-03-08 | Leonard G. Lorch | Dental floss |
US10206765B2 (en) | 2011-01-24 | 2019-02-19 | Leonard G. Lorch | Dental floss |
US9277977B2 (en) | 2011-01-24 | 2016-03-08 | Leonard G. Lorch | Dental floss |
US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
US20130078307A1 (en) | 2011-09-22 | 2013-03-28 | Niconovum Usa, Inc. | Nicotine-containing pharmaceutical composition |
US9084439B2 (en) | 2011-09-22 | 2015-07-21 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US9474303B2 (en) | 2011-09-22 | 2016-10-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US9629392B2 (en) * | 2011-09-22 | 2017-04-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
EP2765989B1 (en) * | 2011-10-13 | 2016-04-13 | Jaleva Pharmaceuticals LLC | Methods and compositions for rapid transbuccal delivery of active agents |
US9907748B2 (en) * | 2011-10-21 | 2018-03-06 | Niconovum Usa, Inc. | Excipients for nicotine-containing therapeutic compositions |
US20130177646A1 (en) * | 2012-01-05 | 2013-07-11 | Mcneil Ab | Solid Nicotine-Comprising Dosage Form with Reduced Organoleptic Disturbance |
US9763928B2 (en) * | 2012-02-10 | 2017-09-19 | Niconovum Usa, Inc. | Multi-layer nicotine-containing pharmaceutical composition |
WO2013188847A1 (en) * | 2012-06-15 | 2013-12-19 | Tonix Pharmaceuticals, Inc. | Compositions and methods for transmucosal absorption |
US20150202168A1 (en) * | 2012-08-17 | 2015-07-23 | Sanovel llac Sanayi Ve Ticaret Anonim Sirketi | Oral film formulations comprising dapoxetine and tadalafil |
US10130120B2 (en) | 2013-03-15 | 2018-11-20 | Altria Client Services Llc | Use of pectin or other anionic polymers in the stabilization and controlled release of nicotine in oral sensorial tobacco products or nicotine containing non-tobacco oral sensorial products |
HRP20240648T1 (hr) | 2013-03-15 | 2024-08-02 | Tonix Pharma Holdings Limited | Eutektičke formulacije ciklobenzaprin hidroklorida i manitola |
CN103284319A (zh) * | 2013-06-20 | 2013-09-11 | 昌宁德康生物科技有限公司 | 一种金雀花碱替代尼古丁口腔雾化液及其制备方法 |
CA2961822A1 (en) | 2014-09-18 | 2016-03-24 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride |
KR101695071B1 (ko) * | 2014-12-26 | 2017-01-11 | 연세대학교 산학협력단 | 액상으로 약물을 분산시킨 필름형태의 약제학적 조성물 |
EP4360653A3 (en) | 2015-03-26 | 2024-07-31 | Patheon Softgels Inc. | Liquisoft capsules |
FR3034991A1 (fr) * | 2015-04-17 | 2016-10-21 | Bertin Pharma | Comprime pharmaceutique bicouche, procede de fabrication et utilisation comme medicament |
WO2017003951A1 (en) * | 2015-06-29 | 2017-01-05 | Phloronol, Inc. | Solid pharmaceutical compositions of brown algae |
WO2017119801A1 (ko) * | 2016-01-08 | 2017-07-13 | 주식회사 씨티씨바이오 | 바레니클린 또는 이의 약학적으로 허용가능한 염을 함유하는 맛 차폐된 구강 투여용 약학 제제 |
WO2017182084A1 (en) | 2016-04-21 | 2017-10-26 | Fertin Pharma A/S | Nicotine delivery product, related uses and oral dosage forms, and methods of production |
WO2017189375A1 (en) * | 2016-04-27 | 2017-11-02 | Axim Biotechnologies, Inc. | Chewing gum composition comprising cannabinoids and nicotine |
US10653639B2 (en) | 2016-05-16 | 2020-05-19 | Cv Sciences, Inc. | Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction |
EP3525792A4 (en) * | 2016-10-11 | 2020-04-22 | Aucta Pharmaceuticals | POWDER FOR ORAL SUSPENSION CONTAINING LAMOTRIGIN |
EP3590498A4 (en) * | 2017-03-03 | 2020-12-16 | CTC Bio, Inc. | PREPARATION WITH INCLUDING COMPLEX OF VARENICLINE OR PHARMACEUTICAL SAFE SALT THEREOF FOR ORAL ADMINISTRATION |
CN118267382A (zh) | 2017-12-11 | 2024-07-02 | 通尼克斯制药控股有限公司 | 用于痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗 |
RU2677125C1 (ru) * | 2018-04-19 | 2019-01-15 | Александр Александрович Кролевец | Способ получения мармелада с наноструктурированным L-аргинином |
EP3598968A1 (en) * | 2018-07-23 | 2020-01-29 | Adamed Pharma S.A. | Solid pharmaceutical cytisine composition |
GB201815420D0 (en) * | 2018-09-21 | 2018-11-07 | Cosmetic Warriors Ltd | Composition |
WO2021144367A1 (en) * | 2020-01-15 | 2021-07-22 | Mcneil Ab | Lozenge |
US20220175662A1 (en) * | 2020-11-14 | 2022-06-09 | Regents Of The University Of Minnesota | Sustained release device for treatment of parkinson's disease and other disorders |
US20220354785A1 (en) * | 2021-04-22 | 2022-11-10 | Nicoventures Trading Limited | Oral lozenge products |
US20230123099A1 (en) * | 2021-10-15 | 2023-04-20 | Fertin Pharma A/S | Dextrose tablets with improved mouthfeel |
CN114088843B (zh) * | 2021-11-26 | 2024-01-30 | 上海皓鸿生物医药科技有限公司 | 一种伐伦克林中间体中亚硝胺类基因毒性杂质的检测方法 |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US352466A (en) * | 1886-11-09 | Geoege cheistopheb huttemeyee | ||
US2253800A (en) * | 1936-01-03 | 1941-08-26 | Myers | Medicinal lozenge and process of froducing the same |
US2311923A (en) * | 1939-06-08 | 1943-02-23 | Iodent Chemical Company | Cough drop |
US3901248A (en) * | 1970-07-22 | 1975-08-26 | Leo Ab | Chewable smoking substitute composition |
US3877468A (en) * | 1970-07-22 | 1975-04-15 | Leo Ab | Chewable tobacco substitute composition |
US3845217A (en) * | 1972-11-16 | 1974-10-29 | Helsingborg L Ab | Buffered smoking substitute compositions |
US4372942A (en) * | 1981-08-13 | 1983-02-08 | Beecham Inc. | Candy base and liquid center hard candy made therefrom |
GB8301659D0 (en) * | 1983-01-21 | 1983-02-23 | Leo Ab | Smoking substitutes |
US4513012A (en) * | 1983-05-13 | 1985-04-23 | Warner-Lambert Company | Powdered center-filled chewing gum compositions |
GB8615676D0 (en) * | 1986-06-26 | 1986-07-30 | Stoppers Co Ltd | Nicotine containing lozenge |
US4762719A (en) * | 1986-08-07 | 1988-08-09 | Mark Forester | Powder filled cough product |
US4789546A (en) * | 1987-02-19 | 1988-12-06 | Consumer Products Corp. | Multiple-layer tablet with contrasting organoleptic characteristics |
US5236713A (en) * | 1987-10-21 | 1993-08-17 | Teikoku Seiyaku Kabushiki Kaisha | Preparation for intermittently releasing active agent applicable to oral cavity |
US4851226A (en) * | 1987-11-16 | 1989-07-25 | Mcneil Consumer Products Company | Chewable medicament tablet containing means for taste masking |
US4906478A (en) * | 1988-12-12 | 1990-03-06 | Valentine Enterprises, Inc. | Simethicone/calcium silicate composition |
US5275822A (en) * | 1989-10-19 | 1994-01-04 | Valentine Enterprises, Inc. | Defoaming composition |
EP0437098A3 (en) * | 1990-01-11 | 1991-09-18 | Warner-Lambert Company | Compressed confectionery tablets with at least two phases and sequential flavour delivery system |
US5075114A (en) * | 1990-05-23 | 1991-12-24 | Mcneil-Ppc, Inc. | Taste masking and sustained release coatings for pharmaceuticals |
US5167242A (en) * | 1990-06-08 | 1992-12-01 | Kabi Pharmacia Aktiebolaq | Nicotine-impermeable container and method of fabricating the same |
US5196436A (en) * | 1990-10-31 | 1993-03-23 | The Procter & Gamble Company | Dextromethorphan antitussive compositions |
CA2068402C (en) * | 1991-06-14 | 1998-09-22 | Michael R. Hoy | Taste mask coatings for preparation of chewable pharmaceutical tablets |
CN1122103A (zh) * | 1993-04-30 | 1996-05-08 | 普罗克特和甘保尔公司 | 包衣药剂组合物 |
IT1264696B1 (it) * | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
SE9303574D0 (sv) * | 1993-11-01 | 1993-11-01 | Kabi Pharmacia Ab | Composition for drug delivery and method the manufacturing thereof |
FR2718020B1 (fr) * | 1994-04-01 | 1996-05-31 | Biotec Centre Sa | Composition galénique mucoadhésive hétérofonctionnelle. |
US5626896A (en) * | 1994-12-09 | 1997-05-06 | A.E. Staley Manufacturing Co. | Method for making liquid-centered jelly candies |
US5810018A (en) * | 1994-12-29 | 1998-09-22 | Monte; Woodrow C. | Method, composition and apparatus for reducing the incidence of cigarette smoking |
US5578336A (en) * | 1995-06-07 | 1996-11-26 | Monte; Woodrow C. | Confection carrier for vitamins, enzymes, phytochemicals and ailmentary vegetable compositions and method of making |
US5776957A (en) * | 1996-11-15 | 1998-07-07 | The University Of Kentucky Research Foundation | Nornicotine enantiomers for use as a treatment for dopamine related conditions and disease states |
US6024981A (en) * | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
GB9707977D0 (en) * | 1997-04-21 | 1997-06-11 | Procter & Gamble | Centre filled confectionery |
US6103260A (en) * | 1997-07-17 | 2000-08-15 | Mcneil-Ppc, Inc. | Simethicone/anhydrous calcium phosphate compositions |
FR2766089B1 (fr) * | 1997-07-21 | 2000-06-02 | Prographarm Lab | Comprime multiparticulaire perfectionne a delitement rapide |
US6358060B2 (en) * | 1998-09-03 | 2002-03-19 | Jsr Llc | Two-stage transmucosal medicine delivery system for symptom relief |
US6248760B1 (en) * | 1999-04-14 | 2001-06-19 | Paul C Wilhelmsen | Tablet giving rapid release of nicotine for transmucosal administration |
US6583160B2 (en) * | 1999-04-14 | 2003-06-24 | Steve Smith | Nicotine therapy method and oral carrier for assuaging tobacco-addiction |
US20010016593A1 (en) * | 1999-04-14 | 2001-08-23 | Wilhelmsen Paul C. | Element giving rapid release of nicotine for transmucosal administration |
DE19927688A1 (de) * | 1999-06-17 | 2000-12-21 | Gruenenthal Gmbh | Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac |
AU3885201A (en) * | 1999-09-20 | 2001-04-24 | Mastercare | Diet and weight control gum and sucker |
GB0002305D0 (en) * | 2000-02-01 | 2000-03-22 | Phoqus Limited | Power material for electrostatic application |
AU2001261744A1 (en) * | 2000-05-19 | 2001-12-03 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
US6814978B2 (en) * | 2000-12-29 | 2004-11-09 | Mcneil-Ppc, Inc. | Process for preparing a soft tablet |
US20020122823A1 (en) * | 2000-12-29 | 2002-09-05 | Bunick Frank J. | Soft tablet containing dextrose monohydrate |
US20020086054A1 (en) * | 2001-01-02 | 2002-07-04 | Jiajiu Shaw | Controlled release system that needs no drilling |
US20030035839A1 (en) * | 2001-05-15 | 2003-02-20 | Peirce Management, Llc | Pharmaceutical composition for both intraoral and oral administration |
US7101573B2 (en) * | 2001-09-28 | 2006-09-05 | Mcneil-Pcc, Inc. | Simethicone solid oral dosage form |
US20030077362A1 (en) * | 2001-10-23 | 2003-04-24 | Panhorst Dorothy A. | Encapsulated flavors as inclusion in candy confections |
US6863901B2 (en) * | 2001-11-30 | 2005-03-08 | Collegium Pharmaceutical, Inc. | Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration |
GB0204772D0 (en) * | 2002-02-28 | 2002-04-17 | Phoqus Ltd | Pharmaceutical dosage forms |
US7670612B2 (en) * | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
EP1449525A1 (en) * | 2003-02-20 | 2004-08-25 | Cross Chem Llc | chewing gum in the form of multi-layer tablets |
WO2006063189A2 (en) * | 2004-12-10 | 2006-06-15 | Novartis Ag | Multi-layered chewing gum tablet with quick disintegration layer |
JP2006232675A (ja) * | 2005-02-22 | 2006-09-07 | Kowa Co | 複合型口腔内溶解用固形製剤 |
US20070092553A1 (en) * | 2005-10-21 | 2007-04-26 | Pfab Lp | Compositions and methods of making rapidly dissolving lonically masked formulations |
US20070269492A1 (en) * | 2006-05-16 | 2007-11-22 | Per Steen | New product and use and manufacture thereof |
US20090004248A1 (en) * | 2007-06-29 | 2009-01-01 | Frank Bunick | Dual portion dosage lozenge form |
-
2009
- 2009-04-27 US US12/430,238 patent/US20100247586A1/en not_active Abandoned
-
2010
- 2010-03-26 AU AU2010201229A patent/AU2010201229A1/en not_active Abandoned
- 2010-03-26 ZA ZA2010/02188A patent/ZA201002188B/en unknown
- 2010-03-26 BR BRPI1001980-4A patent/BRPI1001980A2/pt not_active IP Right Cessation
- 2010-03-26 JP JP2010071926A patent/JP2010229131A/ja active Pending
- 2010-03-26 CA CA2697867A patent/CA2697867A1/en not_active Abandoned
- 2010-03-26 AR ARP100100980A patent/AR076153A1/es not_active Application Discontinuation
- 2010-03-26 NZ NZ584267A patent/NZ584267A/en not_active IP Right Cessation
- 2010-03-26 RU RU2010111715/15A patent/RU2490010C2/ru not_active IP Right Cessation
- 2010-03-26 NZ NZ598993A patent/NZ598993A/en not_active IP Right Cessation
- 2010-03-29 MX MX2010003550A patent/MX2010003550A/es not_active Application Discontinuation
- 2010-03-29 KR KR1020100028173A patent/KR20100108307A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
CA2697867A1 (en) | 2010-09-27 |
ZA201002188B (en) | 2011-12-28 |
JP2010229131A (ja) | 2010-10-14 |
RU2010111715A (ru) | 2011-10-10 |
RU2490010C2 (ru) | 2013-08-20 |
AU2010201229A1 (en) | 2010-11-11 |
US20100247586A1 (en) | 2010-09-30 |
BRPI1001980A2 (pt) | 2011-07-26 |
NZ584267A (en) | 2012-04-27 |
MX2010003550A (es) | 2010-10-05 |
NZ598993A (en) | 2014-02-28 |
KR20100108307A (ko) | 2010-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR076153A1 (es) | Forma de dosificacion intra-oral de multiples porciones con propiedades organolepticas. formulaciones | |
CN101829036B (zh) | 口腔喷雾剂 | |
AR060932A1 (es) | Producto y su uso y elaboracion | |
WO2014093127A3 (en) | Method of administering nicotine, thc, tobacco, cannabidiol or base alkaloid and absorption conditioning unit | |
AR060931A1 (es) | Producto farmaceutico recubierto para la administracion intraoral de nicotina y su uso y elaboracion | |
NO20070887L (no) | Kornformet farmasoytisk preparat med tidsbegrenset frigivelse for oral administrasjon, og intraoral hurtig desintegrerende tablett som inneholder preparatet | |
BRPI0513200A (pt) | uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas | |
ATE355065T1 (de) | Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika | |
AR058133A1 (es) | Metodo de tratamiento y/o prevencion de infecciones en bebes nacidos por cesarea | |
JP2009522376A5 (es) | ||
CY1111369T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη | |
CL2009001025A1 (es) | Composicion de pastilla para chupar que comprende: a) un granulo patron con al menos: un agente tampon alcalino, un modificador de la disolucion y una carga, b) un principio activo de nicotina definido extragranular y al menos un agente tampon alcalino; procedimiento de preparacion; util para eliminar o reducir el uso de tabaco. | |
BRPI0806392A8 (pt) | uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica | |
CO6341514A2 (es) | Método para reducir la variabilidad de la absorción de paracetamol en pacientes con dismotilidad gástrica | |
AR066586A1 (es) | Formulacion farmaceutica liquida para proveer nicotina, su uso y fabricacion | |
CO6491061A2 (es) | Formulacion de omeprazol farmaceutica estable para administracion oral | |
AR073796A1 (es) | Formulaciones de corticosteroides y sus metodos de tratamiento | |
WO2008051527A3 (en) | Sustained release of agents for localized pain management | |
JP2019131596A5 (es) | ||
AR042598A1 (es) | Composiciones de acetaminofeno | |
BRPI0900491A8 (pt) | nova espuma comestível em aerosol | |
AR065301A1 (es) | Formulaciones farmaceuticas solidas de una dispersion homogenea de principios activos cuya solubilidad es dependiente del ph | |
Sahoo | A Pre Induction Administration of One Gram Oral or Intravenous Acetaminophen in Control of Post-Operative Pain: A Comparative Study | |
BR112018072183A2 (pt) | composição farmacêutica, e, método para prevenir uma doença de pele | |
Awan | Orodispersible Tablets–A Novel Approach |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |